DC Chemicals Limited
China
Product Name: SB 239063
Price: $600.0/100mg $1100.0/250mg $2300.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

193551-21-2

193551-21-2 structure

Name: SB 239063
Chemical Name: 4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-ol
CAS Number: 193551-21-2
Molecular Formula: C₂₀H₂₁FN₄O₂
Molecular Weight: 368.40500
Catalog: Signaling Pathways MAPK/ERK Pathway p38 MAPK
Create Date: 2018-12-15 16:45:33
Modify Date: 2024-01-11 17:39:50
SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38α). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. IC50 value: 44 nM ( p38α)Target: p38 MAPKSB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.

Name	4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-ol
Synonyms	trans-1-(4-Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole Kinome_3168 Tocris-1962 SB 239063

Description	SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38α). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. IC50 value: 44 nM ( p38α)Target: p38 MAPKSB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.
Related Catalog	Signaling Pathways >> MAPK/ERK Pathway >> p38 MAPK Research Areas >> Inflammation/Immunology
References	[1]. Bison S, et al. Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats.Eur J Pharmacol. 2011 Jul 1;661(1-3):49-56. Epub 2011 Apr 27. [2]. Ward KW, et al. SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.Pharm Res. 2001 Sep;18(9):1336-44. [3]. Barone FC, et al. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.J Pharmacol Exp Ther. 2001 Feb;296(2):312-21. [4]. Underwood et al (2000) SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J.Pharmacol.Exp.Ther. 293 281. [5]. Legos et al (2002) The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur.J.Pharmacol. 447 37. [6]. Matthew Huentelman, et al. Methods of treating memory loss and enhancing memory performance. US 20120245188 A1.

Density	1.35g/cm3
Boiling Point	594.8ºC at 760 mmHg
Molecular Formula	C₂₀H₂₁FN₄O₂
Molecular Weight	368.40500
Flash Point	313.5ºC
Exact Mass	368.16500
PSA	73.06000
LogP	3.63080
Vapour Pressure	5.42E-15mmHg at 25°C
Index of Refraction	1.655
Storage condition	-20°C

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR	NONH for all modes of transport
WGK Germany	3
RTECS	GV9458000

193551-20-1

~64%

193551-21-2

Literature: SmithKline Beecham Corporation Patent: US6329526 B1, 2001 ;

Precursor 1
193551-20-1
DownStream 0

193551-21-2	143797-62-0
201038-74-6	274252-40-3
1346603-08-4	1431697-90-3
200940-23-4	24570-77-2
791789-61-2	201038-58-6